Omeros Co. (NASDAQ:OMER) Short Interest Update

Omeros Co. (NASDAQ:OMER) was the recipient of a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 8,920,000 shares, a decrease of 16.9% from the November 15th total of 10,730,000 shares. Based on an average trading volume of 701,200 shares, the short-interest ratio is presently 12.7 days. Approximately 16.1% of the shares of the company are sold short.

Institutional Trading of Omeros

Several hedge funds have recently modified their holdings of the business. Barclays PLC lifted its holdings in shares of Omeros by 121.3% in the 3rd quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock valued at $376,000 after buying an additional 51,873 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Omeros by 0.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,339,251 shares of the biopharmaceutical company’s stock valued at $5,318,000 after buying an additional 6,839 shares during the period. MML Investors Services LLC lifted its holdings in shares of Omeros by 19.2% in the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 3,000 shares during the period. Jane Street Group LLC raised its holdings in Omeros by 15.9% during the third quarter. Jane Street Group LLC now owns 58,277 shares of the biopharmaceutical company’s stock worth $231,000 after purchasing an additional 8,010 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new position in Omeros during the third quarter worth $305,000. 48.79% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have commented on OMER. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Omeros in a research note on Thursday, November 14th. StockNews.com raised Omeros from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research note on Thursday, November 14th. Rodman & Renshaw began coverage on Omeros in a research note on Thursday, November 14th. They set a “buy” rating and a $9.00 price objective for the company. Finally, RODMAN&RENSHAW raised Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. Three investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Omeros has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

Omeros Price Performance

OMER opened at $7.63 on Friday. The business has a 50 day simple moving average of $6.53 and a 200-day simple moving average of $4.97. The stock has a market capitalization of $442.16 million, a P/E ratio of -3.30 and a beta of 1.97. Omeros has a 12 month low of $2.61 and a 12 month high of $12.65.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.